Table 3 Non-biologic treatments for patients with CRSwNP, stratified by surgery and biologic use

Patients with corticosteroid use, n (%)

All OCS use*

2717 (45.3)

442 (68.8)

2275 (42.5)

 < 0.001

48 (87.3)

306 (72.9)

0.021

394 (67.1)

1969 (39.9)

 < 0.001

CRSwNP-related OCS*

865 (14.4)

136 (21.2)

729 (13.6)

 < 0.001

37 (67.3)

248 (59.0)

0.242

99 (16.9)

481 (9.7)

 < 0.001

Intranasal corticosteroids

1992 (33.2)

282 (43.9)

1710 (31.9)

 < 0.001

29 (52.7)

185 (44.0)

0.224

253 (43.1)

1525 (30.9)

 < 0.001

Patients with antibiotic (oral) use, n (%)

Amoxicillin

1836 (30.6)

234 (36.4)

1602 (29.9)

 < 0.001

28 (50.9)

199 (47.4)

0.622

206 (35.1)

1403 (28.4)

 < 0.001

Azithromycin

1010 (16.8)

147 (22.9)

863 (16.1)

 < 0.001

14 (25.5)

74 (17.6)

0.16

133 (22.7)

789 (16.0)

 < 0.001

Clarithromycin

169 (2.8)

36 (5.6)

133 (2.5)

 < 0.001

4 (7.3)

27 (6.4)

0.772

32 (5.5)

106 (2.1)

 < 0.001

Doxycycline

837 (14.0)

122 (19.0)

715 (13.4)

 < 0.001

14 (25.5)

87 (20.7)

0.419

108 (18.4)

628 (12.7)

 < 0.001

Erythromycin

4 (0.1)

1 (0.2)

3 (0.1)

0.364

0 (0)

0 (0)

 > 0.999

1 (0.2)

3 (0.1)

0.362

Treatments used in the 30 days before earliest sinus surgery, n (%)

OCS

154 (33.0)

–

–

–

27 (49.1)

127 (30.9)

0.007

–

–

–

Intranasal corticosteroids

53 (11.4)

–

–

–

11 (20.0)

42 (10.2)

0.032

–

–

–

Antibiotics (oral)

78 (16.7)

–

–

–

8 (14.5)

70 (17.0)

0.643

–

–

–

Treatments used in the 30 days on or after earliest sinus surgery n, (%)

OCS

125 (26.8)

–

–

–

15 (27.3)

110 (26.8)

0.936

–

–

–

Intranasal corticosteroids

83 (17.8)

–

–

–

10 (18.2)

73 (17.8)

0.939

–

–

–

Antibiotics (oral)

123 (26.4)

–

–

–

16 (29.1)

107 (26.0)

0.629

–

–

–